Free Access
Tableau III.
Traitement féminisant chez les femmes transgenres (FT).
| Œstrogènes : 17b-œstradiol | Posologie | |
|---|---|---|
| Oral : Provames®, Oromone® | 2 à 6 mg/j | |
| Gels transdermiques : Œstrodose®, Estreva® | 0,025 à 0,2 mg/j | |
| Patchs transdermiques : Vivelledot®, Dermestryl® (liste non exhaustive) | 0,025 à 0,2 mg/j | |
| Anti-androgènes | Posologie | Surveillance |
| Acétate de cyprotérone | 25-50 mg/j | IRM cérébrale et fonction hépatique |
| Spironolactone | 100-300 mg/j | kaliémie, pression artérielle |
| Agonistes de la GnRH : Décapeptyl® 3 mg LP Décapeptyl® 11,5 mg LP (liste non exhaustive) | Une injection/mois Une injection/3 mois | Effet flare up à la 1re injection |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.